Results 161 to 170 of about 9,281 (210)
International audienceDifferent microbial antigens, by signaling through toll-like receptors (TLR), may contribute to Th17-mediated autoimmune diseases, such as neuromyelitis optica spectrum disorder (NMOSD).
Renato Santana Aguiar +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Continuum
This article reviews the clinical features, MRI characteristics, diagnosis, and treatment of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
openaire +2 more sources
This article reviews the clinical features, MRI characteristics, diagnosis, and treatment of aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
openaire +2 more sources
NMOSD and MOGAD: Updates on diagnostic criteria
Revue NeurologiqueRecently, diagnostic criteria for demyelinating diseases, including multiple sclerosis, have been updated with a focus on imaging and fluid markers. The upcoming criteria for neuromyelitis optica (NMO) introduce several clinico-radiological updates, and highlight the need for accurate determination of AQP4-IgG status.
R, Marignier, M, Leal Rato
openaire +2 more sources
Unveiling Misdiagnosis: Rethinking Seronegative NMOSD
Multiple Sclerosis JournalSeronegative neuromyelitis optica spectrum disorder (NMOSD) is a diagnostic challenge. This study aimed to characterize misapplication of the 2015 international criteria for seronegative NMOSD. We reviewed 35 consecutive seronegative NMOSD referrals to a tertiary center.
Mary V. Lang +6 more
openaire +2 more sources
Multiple Sclerosis Journal
Background: Anti-interleukin-6 receptor (anti-IL6R) therapy has demonstrated efficacy in AQP4 + NMOSD, and emerging evidence suggests a similar benefit in patients with MOGAD. Objectives: This study aimed to evaluate the role of anti ...
Chloé Comet +16 more
openaire +2 more sources
Background: Anti-interleukin-6 receptor (anti-IL6R) therapy has demonstrated efficacy in AQP4 + NMOSD, and emerging evidence suggests a similar benefit in patients with MOGAD. Objectives: This study aimed to evaluate the role of anti ...
Chloé Comet +16 more
openaire +2 more sources
Proceedings of the BCTRIMS 24th Annual Meeting, 2023
Raquel Vassão Araujo +3 more
openaire +1 more source
Raquel Vassão Araujo +3 more
openaire +1 more source

